title: [Efficacy of treatment with I(131) in paediatric Graves disease].
abstract: BACKGROUND
  Radioiodine is an important therapeutic option in young patients with Grave's disease (GD). In the United States it is a widespread therapy, but in Europe its use in paediatrics is still controversial.
  
  
  OBJECTIVE
  To report our experience in radioiodine therapy of paediatric GD patients and analyse its effectiveness and safety.
  
  
  METHODS
  We retrospectively studied our paediatric population (<18 years of age) with GD, diagnosed from 1982 to 2012. A curative option was offered to patients who did not respond to anti-thyroid drug (AT) at puberty. We analysed, the patient characteristics, TSH, T4, T3 and thyroid antibodies levels, AT response, remission post I(131), side effects, and hypothyroidism rates.
  
  
  RESULTS
  A total of 50 patients were diagnosed with GD from 1982 to 2012. All patients received AT as initial treatment (mean duration: 35.3±25.9 months). Permanent remission was achieved in 46%. Thyroidectomy was performed in 5 patients, and 14 patients received I(131) (mean dose: 10.9±1.09 mCi). Remission with I(131) was obtained in 100%. The rate of permanent hypothyroidism was 90%. There was no progression of ophthalmopathy or side effects in any patients treated with I(131.)
  
  
  CONCLUSIONS
  Radioiodine treatment of paediatric GD patients is safe, leads to complete remission at the expense of hypothyroidism, and does not exacerbate ophthalmopathy. It can be considered in patients older than 5 years, who do no not respond to AT or with significant side effects with this medication.
authors.affiliation: Unidad de Diabetes y Endocrinología Pediátrica, Servicio de Pediatría, Hospital Universitario Ramón y Cajal, Madrid, España. Electronic address: patrienes@msn.com.
authors.forename: P
authors.initials: P
authors.lastname: Enes Romero
authors.affiliation: Unidad de Diabetes y Endocrinología Pediátrica, Servicio de Pediatría, Hospital Universitario Ramón y Cajal, Madrid, España.
authors.forename: M
authors.initials: M
authors.lastname: Martín-Frías
authors.affiliation: Servicio de Medicina Nuclear, Hospital Universitario Ramón y Cajal, Madrid, España.
authors.forename: M
authors.initials: M
authors.lastname: de Jesús
authors.affiliation: Servicio de Medicina Nuclear, Hospital Universitario Ramón y Cajal, Madrid, España.
authors.forename: C
authors.initials: C
authors.lastname: Caballero Loscos
authors.affiliation: Unidad de Diabetes y Endocrinología Pediátrica, Servicio de Pediatría, Hospital Universitario Ramón y Cajal, Madrid, España.
authors.forename: M
authors.initials: M
authors.lastname: Alonso Blanco
authors.affiliation: Unidad de Diabetes y Endocrinología Pediátrica, Servicio de Pediatría, Hospital Universitario Ramón y Cajal, Madrid, España.
authors.forename: R
authors.initials: R
authors.lastname: Barrio Castellanos
mesh_terms: D002648:Child; D005260:Female; D006111:Graves Disease / Q000532:radiotherapy*; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D007457:Iodine Radioisotopes
keywords: (131)I; Children; Edad pediátrica; Enfermedad de Graves; Graves disease; I(131); Radioiodine therapy; Radioyodo